REPL
Replimune Group, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website replimune.com
- Employees(FY) 284
- ISIN US76029N1063
Performance
-4.31%
1W
-9.93%
1M
-16.69%
3M
-37.6%
6M
-23.61%
YTD
-66.97%
1Y
Profile
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Investment Analysis Report: REPL
Overview
REPL is a biotechnology company operating in the Health Technology sector with a market capitalization of $474.53 million. In this report, we will conduct a comprehensive analysis of REPL's financial statements over the past three years to evaluate its valuation, financial health, earnings and revenue gr...
Technical Analysis of REPL 2024-05-10
Overview:
In analyzing the technical indicators for the last 5 days of the stock, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed d...
Recent News & Updates
- 2024-05-16 01:53
REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024(Investorplace)
- 2024-05-15 20:00
- 2024-04-07 17:00
- 2024-04-07 05:00
- 2024-04-04 08:00
- 2024-04-03 20:00
- 2024-03-26 07:30
- 2024-03-25 19:30
- 2024-03-11 09:55
- 2024-03-10 21:55
- 2024-03-08 12:00
- 2024-03-07 23:00
- 2024-03-06 08:00
- 2024-03-05 19:00
- 2024-03-05 08:00
Replimune to Present at Three Upcoming Investor Conferences(GlobeNewswire)
- 2024-03-04 19:00
Replimune to Present at Three Upcoming Investor Conferences(Globenewswire)
- 2024-02-27 03:30
12 Best Medical Stocks to Buy Under $10(Insider Monkey)
- 2024-02-23 09:55
- 2024-02-22 20:55
- 2024-02-08 08:00
- 2024-02-07 19:42
- 2024-02-07 19:00
- 2024-01-22 10:54
15 Small-Cap Stocks with High Potential(Insider Monkey)
- 2024-01-16 03:59
- 2024-01-15 14:59
- 2023-12-28 08:00
- 2023-12-27 19:00
- 2023-12-07 05:40
- 2023-12-05 07:32
- 2023-12-05 07:10
Page 1 of 5
previousnext